Submit Separate Retrospective, Prospective Study data of subjects: CDSCO Panel Tells Takeda on Velaglucerase alfa study
New Delhi: Regarding the post-marketing surveillance study of the drug major Takeda Pharmaceutical's Velaglucerase alfa injection, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to present data separately for a retrospective and prospective study of the subjects who participated in the study and to submit patient wise data regarding size reduction of organ- liver and spleen.
VPRIV (velaglucerase alfa) is indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.
Gaucher disease type 1 (GD1) is the most common form of Gaucher disease. Like other types of Gaucher disease, GD1 is caused when not enough glucocerebrosidase (GBA) is made. GBA is an important enzyme that breaks down a fatty chemical called glucocerebroside. Because the body cannot break down this chemical, fat-filled Gaucher cells build up in areas like the spleen, liver, and bone marrow. Symptoms of GD1 include enlarged spleen and liver, low blood cell counts, bleeding problems, and bone disease. The symptoms can range from mild to severe and may appear anytime from childhood to adulthood. Gaucher disease is caused by changes in the GBA gene and is inherited in an autosomal recessive manner. Diagnosis is suspected by clinical symptoms and confirmed by measuring GBA enzyme activity or genetic testing.
1. The firm has to present data separately for retrospective and prospective study of the subjects who participated in the study.2. To submit patient wise data regarding size reduction of organ- liver and spleen.
